Immunic Appoints Michael A. Panzara as Chief Medical Officer

Immunic, Inc., a biotechnology firm focused on oral therapies for neurologic diseases, has announced the appointment of Dr. Michael A. Panzara as Chief Medical Officer. Dr. Panzara brings over 25 years of experience in neurology drug development, with a notable background at companies like Sanofi Genzyme and Biogen. His expertise includes overseeing the global regulatory approvals of several multiple sclerosis therapies.

Dr. Panzara's appointment comes as Immunic advances its lead program, vidofludimus calcium, through phase 3 clinical trials for relapsing multiple sclerosis. His role will involve guiding the clinical development, medical affairs, and regulatory strategies, pivotal to supporting the company's transition into a commercial-stage entity.

Dr. Panzara succeeds Dr. Andreas Muehler, who will remain as a consultant. Dr. Muehler commended the progress of vidofludimus calcium under his tenure and expressed confidence in Dr. Panzara's leadership to further advance the company's goals.